HSD17B7

Across TCGA pan-cancer cohorts, HSD17B7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HSD17B7 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher HSD17B7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HSD17B7 expression acts as an unfavorable survival marker.

SKCM and STAD are the cancer types where HSD17B7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	II,III,IV	0.228	0.742	<.001	18	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

HSD17B7–SKCM (OS)

Open the SKCM breakdown →